Prominent publications by Elı́as Campo

KOL Index score: 20119

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis.

PATIENTS AND METHODS: We determined the correlation between presence of ...

Known for Concurrent Expression |  Patients Dlbcl |  Myc Bcl2 Proteins |  Lymphoma Treated |  Doxorubicin Vincristine
KOL Index score: 19563

Mantle cell lymphoma (MCL) is molecularly characterized by bcl-1 rearrangement and cyclin D1 gene overexpression. Some aggressive variants of MCL have been described with blastic or large cell morphology, higher proliferative activity, and shorter survival. The cyclin-dependent kinase inhibitors (CDKIs) p21Waf1 and p16INK4a have been suggested as candidates for tumor-suppressor genes. To determine the role of p21Waf1 and p16INK4a gene alterations in MCLs, we examined the expression, ...

Known for Aggressive Variants |  P21waf1 Gene |  Mantle Cell Lymphomas |  Expression P16ink4a |  Cyclin D1
KOL Index score: 17925

Genomic studies have revealed the complex clonal heterogeneity of chronic lymphocytic leukemia (CLL). The acquisition and selection of genomic aberrations may be critical to understanding the progression of this disease. In this study, we have extensively characterized the mutational status of TP53, SF3B1, BIRC3, NOTCH1, and ATM in 406 untreated CLL cases by ultra-deep next-generation sequencing, which detected subclonal mutations down to 0.3% allele frequency. Clonal dynamics were ...

Known for Subclonal Tp53 |  Clinical Impact |  Chronic Lymphocytic Leukemia |  Mutations Clonal |  Longitudinal Samples
KOL Index score: 17511

Most high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements are aggressive B-cell lymphomas. Occasional double-hit follicular lymphomas have been described but the clinicopathological features of these tumors are not well known. To clarify the characteristics of double-hit follicular lymphomas, we analyzed 10 cases of double-hit follicular lymphomas and 15 cases of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements for clinicopathological and ...

Known for Follicular Lymphoma |  Protooncogene Proteins |  Bcl6 Rearrangements |  Myc Bcl2 |  Grade Cell
KOL Index score: 17278

The molecular mechanisms underlying the pathogenesis of aggressive lymphomas and the histological transformation of indolent variants are not well known. To determine the role of p16(INK4a) gene alterations in the pathogenesis of non-Hodgkin's lymphomas (NHLs) and the histological progression of indolent variants, we have analyzed the expression, deletions, and mutations of this gene in a series of 112 NHLs. Hypermethylation of the gene was also examined in a subset of tumors with lack ...

Known for Aggressive Variants |  Neoplastic Genes |  Homozygous Deletion |  Protein Expression |  Mutations Hypermethylation
KOL Index score: 17263

p53 is a tumour suppressor gene which is often found to be inactivated in most types of human cancer. p53 is a transcription factor, the inactivation of which may lead to significant variations in the levels of p53 downstream proteins, such as p21WAF1/CIP1 and MDM2. In view of the significance of p21WAF1/CIP1 and MDM2 as wild-type (wt) p53 targets, this study was undertaken to monitor the varying expression of these proteins in non-Hodgkin's lymphomas (NHLs) in relation to p53 gene ...

Known for Mdm2 Expression |  P53 Mutations |  P21waf1 Cip1 |  Herpesvirus 4 |  Oncogene Proteins
KOL Index score: 17103

Two types of vulvar squamous cell carcinomas (VSCCs) are recognized according to their relationship to human papillomavirus (HPV). Basaloid or warty carcinomas are considered HPV-associated tumors, whereas differentiated keratinizing neoplasms are considered non-HPV-associated. Recently, immunohistochemical detection of p16 and p53 has been proposed to differentiate these 2 types of VSCCs. We conducted a histologic study with immunohistochemical evaluation of p16 and p53 and HPV ...

Known for P16 P53 |  Vulvar Squamous |  Cell Carcinomas |  Hpv Positive |  Tumor Carcinoma
KOL Index score: 16381

Chronic lymphocytic leukemia (CLL) is an incurable disease derived from the monoclonal expansion of CD5(+) B lymphocytes. High expression levels of ZAP-70 or CD38 and deletions of 17p13 (TP53) and 11q22-q23 (ATM) are associated with poorer overall survival and shorter time to disease progression. DNA damage and p53 play a pivotal role in apoptosis induction in response to conventional chemotherapy, because deletions of ATM or p53 identify CLL patients with resistance to treatment. ...

Known for Chronic Lymphocytic Leukemia |  Antitumor Activity |  Cll Cells |  Induction P73 |  Protein P53
KOL Index score: 16012

The majority of anaplastic large cell lymphomas (ALCL) are associated with chromosomal abnormalities affecting the anaplastic lymphoma kinase (ALK) gene which result in the expression of hybrid ALK fusion proteins in the tumor cells. In most of these tumors, the hybrid gene comprises the 5′ region of nucleophosmin (NPM) fused in frame to the 3′ portion of ALK, resulting in the expression of the chimeric oncogenic tyrosine kinase NPM-ALK. However, other variant rearrangements have been ...

Known for Cell Lymphoma |  Anaplastic Large |  Alk Expression |  Molecular Characterization |  Neoplastic Humans
KOL Index score: 15472

p27 is a cyclin-dependent kinase inhibitor that plays a critical role in regulating G(1)/S progression, and whose activity is, in part, regulated through interactions with D-type cyclins. Mantle cell lymphoma (MCL) is characterized by the t(11;14) translocation resulting in deregulated cyclin D1. We previously showed that p27 expression in MCL, as assessed by immunohistochemistry (IHC), does not show the usual inverse relationship to proliferate seen in most other lymphomas that do not ...

Known for Cyclin D1 |  Mantle Cell |  Human Pair |  Kinase Inhibitor |  P27 Protein
KOL Index score: 15366

BACKGROUND: Nm23 is a gene associated with low tumor metastatic potential and has been proposed to be a metastasis suppressor gene. Nm23 is localized on chromosome 17q21.3-22, whereas the p53 suppressor gene is on 17p13. Allelic deletions of chromosome 17 have been related to the progression of colorectal carcinomas. The purpose of this study was to analyze the allelic deletions of Nm23 and p53 in colorectal carcinomas and to assess their prognostic significance in the evolution of the ...

Known for Colorectal Carcinomas |  Prognostic Significance |  Allelic Deletions |  P53 Genes |  Loss Heterozygosity
KOL Index score: 15319


Mantle cell lymphoma (MCL) is molecularly characterized by bcl-1 rearrangement and cyclin D1 gene overexpression. Some aggressive variants of MCL have been described with blastic or large cell morphology, higher proliferative activity, and shorter survival. The cyclin-dependent kinase inhibitors (CDKIs) p21Waf1 and p16INK4a have been suggested as candidates for tumor-suppressor genes. To determine the role of p21Waf1 and p16INK4a gene alterations in MCLs, we ...

Known for Aggressive Variants |  P16ink4a Gene |  Typical Mcls |  Mantle Cell Lymphomas |  Loss Expression
KOL Index score: 15317

p27Kip1 is a cyclin-dependent kinase inhibitor that regulates the decision to enter S phase or withdraw from the cell cycle. In resting cells, the level of p27Kip1 provides an inhibitory threshold above which G1 cyclin D/E/cyclin-dependent kinases accumulate before activation; however, in cycling cells, p27Kip1 protein is sequestered by high levels of active cyclin D/cyclin-dependent kinase 4 complexes. As a group, the cyclin-dependent kinase inhibitors have been proposed to act as tumor ...

Known for Cell Lymphomas |  Dependent Kinase |  P27kip1 Expression |  Proliferation Rate |  Blastic Variant
KOL Index score: 15269

ALK-positive large B-cell lymphoma is an aggressive lymphoid neoplasm characterized by a monomorphic proliferation of immunoblast-like cells expressing a plasmablastic phenotype and carrying ALK rearrangements. MYC rearrangements are frequent in plasmablastic lymphomas, advanced plasma cell myelomas and a subgroup of diffuse large B-cell lymphomas, but their presence in ALK-positive large B-cell lymphomas is unknown. MYC expression is downregulated by BLIMP1, a master modulator of plasma ...

Known for Cell Lymphomas |  Myc Rearrangements |  Positive Large |  Plasmablastic Differentiation |  Lymphoma Kinase


Elı́as Campo: Influence Statistics

Sample of concepts for which Elı́as Campo is among the top experts in the world.
Concept World rank
microscopic examination method #1
notch1 mutations subsets #1
haematopathology society #1
sox11negative #1
interaction bortezomib #1
ighv cll #1
increased messenger #1
patients primary wr #1
nos2 rs2779251 #1
tnfrsf14 gene #1
fixed paraffinembedded tissues #1
wr lymphomas #1
spared temporal artery #1
conventional mcls #1
stereotyped subsets implications #1
notch1mutated patients #1
symptoms flipi #1
bcr kinase inhibitor #1
mutated mantle #1
tenktls #1
subsets frequency #1
controlling oncogenic #1
genes epigenetic regulators #1
notch1mutated cll cells #1
iqs019 #1
p21waf1 gene #1
oncogenic roads #1
inhibitor cpi203 resistance #1
7q313q323 #1
residual recurrent disease #1
cell transformation flipi #1
key oncogenic factor #1
cases lmp1 deletions #1
mutated cll #1
dll4 stimulation #1
mature bcell neoplasm #1
lung tumorigenesis studies #1
omp52m51 effects #1
q2231 #1
zap70 normal cells #1
abstractcdc25 #1
tissue biopsies diagnosis #1
patients sparc cells #1
il1rn il6 #1
diffuse map kinase #1
cxcr4 cooperates #1
major subsets existence #1
mcls p16ink4a #1
terminal bcell differentiation #1
expression deletions #1

Key People For Cell Lymphoma

Top KOLs in the world
Elaine S Jaffe
cell lymphoma lymphoid neoplasms situ hybridization
Randy D Gascoyne
cell lymphoma diffuse large gene expression
Nancy Lee Harris
cell lymphoma abdominal pain cyclin d1
Elı́as Campo
cell lymphoma chronic lymphocytic leukemia cyclin d1
Dennis D Weisenburger
cell lymphoma bone marrow situ hybridization
James Olen Armitage
cell lymphoma bone marrow complete remission

Elı́as Campo:Expert Impact

Concepts for whichElı́as Campohas direct influence:Cell lymphoma,  Mantle cell lymphoma,  Chronic lymphocytic leukemia,  Follicular lymphoma,  Chronic lymphocytic,  Mantle cell,  Large bcell,  Cyclin d1.

Elı́as Campo:KOL impact

Concepts related to the work of other authors for whichfor which Elı́as Campo has influence:Cell lymphoma,  Diffuse large,  Gene expression,  Chronic lymphocytic leukemia,  Breast cancer,  Multiple myeloma,  Cyclin d1.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Centro de Investigación Biomédica en Red, Cáncer (CIBERONC), Madrid, Spain. | Hematopathology Unit, Hospital Clínic of Barcelona, Barcelona, Spain. | Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. | Hematopathol

FREE Custom List